Revenue distribution by sectors:

• Pharmaceuticals: approx. 85%
• Biotechnology: approx. 10%
• Other: approx. 5%

TOP 3 markets and their percentage shares:

• Japan: approx. 40%
• USA: approx. 30%
• Europe: approx. 20%

Daiichi Sankyo Company, Limited generates the majority of its revenue from the pharmaceutical sector, with a significant portion of the income coming from the development and sale of medications. The Japanese market remains the largest single market for the company, followed by the USA and Europe, which are also significant sources of revenue. These markets are crucial for the company's strategic direction and growth.

Production sites of Daiichi Sankyo:

1. Japan: Several production facilities, including plants in Hiratsuka, Onahama, and Takatsuki.
2. Germany: Production site in Pfaffenhofen.
3. Brazil: Plant in Barueri.
4. India: Production facilities in collaboration with Sun Pharmaceutical Industries.

Daiichi Sankyo operates several production sites worldwide, with a focus on Japan. The plants in Germany and Brazil are part of the company's international expansion strategy. In India, Daiichi Sankyo collaborates with local partners to expand production capacities and better serve the Asian market.

Focus on Oncology: Daiichi Sankyo has strongly focused on the development of cancer drugs, especially on antibody-drug conjugates (ADCs).

Partnerships and Collaborations: The company has formed strategic alliances with other pharmaceutical companies to expand its research capabilities and tap into new markets.

Investments in Research and Development: A significant portion of the budget is invested in research and development to develop innovative therapies and strengthen the product pipeline.

Daiichi Sankyo pursues a growth strategy based on strengthening its position in the field of oncology. By developing and marketing innovative cancer treatments, especially ADCs, the company aims to increase its market share and bring new therapies to market faster.

In addition, Daiichi Sankyo relies on strategic partnerships to expand its reach and leverage synergies. These collaborations enable the company to maximize its research capabilities while minimizing risks.

The continuous investments in research and development underscore Daiichi Sankyo's commitment to being at the forefront of medical innovation and ensuring long-term growth.

Main raw materials: Pharmaceutical active ingredients, chemicals, packaging materials
Main importing countries: China, India, Germany, USA

Daiichi Sankyo Company, Limited, as a leading pharmaceutical company, imports a variety of raw materials and materials necessary for the production of their medications. These include pharmaceutical active ingredients and special chemicals, which are often sourced from countries like China and India, as these countries are significant producers of pharmaceutical raw materials.

Packaging materials necessary for the safe and effective distribution of the products are often imported from industrialized countries like Germany and the USA, known for their high-quality packaging technologies.

This import strategy enables Daiichi Sankyo to produce high-quality products while optimizing costs by leveraging the respective strengths of the supplying countries.

Market share in the pharmaceutical industry: 3.5% (2024, estimate)
R&D investments: 20% of revenue (2023)
Patents: Over 1,000 active patents (2023)

Daiichi Sankyo Company, Limited has a significant competitive advantage in the pharmaceutical industry, which is manifested by several factors. The company continuously invests a considerable portion of its revenue in research and development, strengthening its innovative power and fostering the pipeline of new drugs.

With over 1,000 active patents, Daiichi Sankyo secures a technological edge and protects its products from imitators. This enables the company to bring unique products to the market and stand out from the competition.

In addition, Daiichi Sankyo benefits from a strong global presence and strategic partnerships that facilitate access to new markets and increase distribution reach. Together, these factors give the company a robust competitive advantage in the dynamic and highly competitive pharmaceutical industry.

Institutional investor share: 45% (estimated, 2025)
Insider purchases/sales: No significant transactions reported (2025)

The institutional investor share in Daiichi Sankyo is estimated to be around 45%. This reflects the confidence of institutional investors in the company, which plays a significant role in the pharmaceutical industry.

No significant insider purchases or sales were reported in 2025. This could indicate that the management and other insiders currently do not expect significant changes in the company's valuation.

Market share of Daiichi Sankyo: 4.5% (estimated for 2025)

Top competitors and their market shares:

1. Pfizer Inc. - 9.8%
2. Roche Holding AG - 8.7%
3. Novartis AG - 8.3%
4. Johnson & Johnson - 7.9%
5. Merck & Co., Inc. - 7.2%
6. Sanofi - 6.5%
7. AstraZeneca PLC - 5.9%
8. GlaxoSmithKline plc - 5.4%
9. Bristol-Myers Squibb Company - 5.0%
10. Daiichi Sankyo Company, Limited - 4.5%

Moat of Daiichi Sankyo:

Daiichi Sankyo has a moderate moat, mainly supported by its strong research and development department and its specialized medications in the field of oncology. The company has made significant progress in the development of cancer drugs in recent years, giving it a certain competitive advantage.

However, compared to its competitors, Daiichi Sankyo's moat is less pronounced. Companies like Pfizer and Roche tend to have a stronger moat due to their broader product range, larger financial resources, and stronger global presence. These companies benefit from extensive patents, established brands, and a broad international market presence, giving them a significant advantage.

In summary, while Daiichi Sankyo has specific strengths that allow it to be successful in certain niche markets, it possesses a less pronounced moat compared to industry leaders.

Revenue Growth: 8.5% (2024)
R&D Expenses: 20% of revenue (2024)
Net Income Growth: 10% (2024)

Daiichi Sankyo recorded a revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful launches of new drugs. Particularly noteworthy is the high proportion of expenses allocated to research and development, amounting to 20% of revenue. This demonstrates the company's commitment to investing in innovative therapies, which could lead to a strong competitive position in the long term.

The 10% net income growth in 2024 suggests that the company not only increased its revenue but also operated more efficiently. This efficiency improvement could be a result of cost-cutting measures or enhanced production performance.

Overall, Daiichi Sankyo exhibits a solid financial performance with a clear focus on innovation and growth. This could make the company an attractive investment, especially for investors interested in long-term growth opportunities in the pharmaceutical sector.

Dividend yield: 2.5% (2025, estimated)
Dividend history: Continuous payout in the last 5 years

Daiichi Sankyo Company, Limited has pursued a consistent dividend policy in recent years. The dividend yield is currently around 2.5%, which is competitive compared to other companies in the pharmaceutical industry.

Over the past five years, the company has regularly distributed dividends, indicating a reliable payout policy. This continuity demonstrates Daiichi Sankyo's commitment to providing shareholders with stable returns, despite the volatile market conditions in the pharmaceutical industry.